【摘要】 目的:观察思密达与美常安联合应用对腹泻型肠易激综合征(IBS)的治疗效果。方法:60例腹泻型IBS患者随机分为三组:联合用药组21例同时服思密达3 g,tid及美常安胶囊500 mg,tid,另两组分别服思密达(18例)或美常安(21例),剂量同前。记录治疗前后患者的症状、大便次数、大便性状。结果:联合用药组在服药d 7时症状总评分已比治疗前下降78.1%,每日大便次数、大便性状评分已接近正常,与思密达组或美常安组比较,差异有统计学意义(P<0.05),未观察到联合用药有明显的不良反应。结论:联合应用作用机制不同的思密达与美常安能迅速、安全地缓解腹泻型IBS的病情。更多还原

【Abstract】 Objective:To evaluate the efficacy of combination of smectite with Medilac-s for diarrhea-predominent irritable bowel syndrome(IBS).Methods:Sixty patients with IBS were randomized to receive one of three treatment regimens: smectite 3 g plus Medilac-s 500 mg(tid,n=21);smectite alone(3 g,n=18)or Medilac-s alone(500 mg,tid,n=21).The efficacy was assessed based on the improvement of clinical symptoms,frequency and Bristol score of stools before and after treatment.Results: The patients receiving the bi-therapy experienced the reduction of symptoms by 78.1%,and the normal bristol score of stool and the frequency of bowel movement at the end of 7-day treatment.Conclusion: Combination of smectite with Medilac-s offered effective and safe improvement for patients with diarrhea-predominant irritable bowel syndrome.更多还原